Harnessing big data for precision medicine: A panel of experts elucidates the data challenges and proposes key strategic decisions points  by Barash, Carol Isaacson et al.
Applied & Translational Genomics 4 (2015) 10–13
Contents lists available at ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atgHarnessing big data for precision medicine: A panel of experts elucidates the data
challenges and proposes key strategic decisions pointsCarol Isaacson Barash ⁎, Keith O. Elliston, W. Andrew Faucett, Jonathan Hirsch, Gauri Naik,
Alice Rathjen, Grant Wood⁎ Corresponding author.
E-mail address: cibarash@helixhealthadvisors.com (C.
http://dx.doi.org/10.1016/j.atg.2015.02.002a b s t r a c tA group of disparate translational bioinformatics experts convened at the 6th Annual Precision Medicine
Partnership Meeting, October 29–30, 2014 to discuss big data challenges and key strategic decisions needed to
advance precision medicine, emerging solutions, and the anticipated path to success. This article reports the
panel discussion.Article
A group of domain experts representing translational bioinformatics
companies, precision medical IT for health care institutions and leading
health care organizations convened at the 6th Annual Precision Medi-
cine Partnership Meeting, October 29–30, 2014 to discuss big data chal-
lenges and key strategic decisions needed to advance precision
medicine, emerging solutions, and the anticipated path to success.
Panelists:
• Keith O. Elliston, Ph.D., Chief Executive Ofﬁcer, TranSMART Founda-
tion
• W. Andrew Faucett, MS, LGC, Director of Policy & Education, Ofﬁce of
the Chief Scientiﬁc Ofﬁcer, Geisinger Health System
• Jonathan Hirsch, Founder & President, Syapse
• Gauri Naik, Ph.D. Chief Scientiﬁc Ofﬁcer, Optra, Inc.
• Alice Rathjen, Founder & Chief Executive Ofﬁcer, DNA Guide
• Grant Wood, Senior IT Strategist, Clinical Genetics Institute, Inter-
mountain Health Care
• Moderator: Carol Isaacson Barash, Ph.D., Managing Partner, Helix
Health Advisors
Deﬁning the big data problem in precision medicine
We tend to think of data as bytes of information and perhaps lose
sight of the fact that the source of big data in precision medicine is the
human body. Data sources, in other words, have normative beliefs and
values about the accessibility and use of their information. The dataI. Barash).volume problem starts with the roughly 20,000 genes in each of our
bodies, the enormous number of variants within each of those genes,
within each of those organs andwithin each of those cells, and also clin-
ical chemistry, imaging, epigenetic,molecular proﬁling, tumor proﬁling,
and omics data.
Experts agreed that high volume is one vector of the data problem
but the other is complexity. They shared some emerging success strate-
gies that are worth noting. Data storage is transitioning from ware-
houses to the cloud now that people are beginning to be convinced of
cloud security. Geisinger, for example, is storing research exomes in
the cloud. Given that two years ago healthcare institutions were deeply
dubious about moving away from storage in data warehouses, experts
saw this transition as a tremendous progress.
Elliston: Advancing precisionmedicine requires a different trajecto-
ry than has been historically the case. Discovery, development and ap-
plication require patient centric data to move from the clinic to the
research environment and back. The challenge is how tomove high vol-
umes of complex data in this loop. The historical practice of people de-
veloping, purchasing and implementing large enterprise platforms isn't
working in precision medicine. Instead collaboration, crowd sourcing,
and open sourcing are the way things are going. Open Clinica and I2B2
are good examples of open source platforms that integrate disparate
types of data, but theproblem is that they don't integratemolecular pro-
ﬁling and other types of high-dimensional research data. TranSMART
integrates clinical information with research data to bring all the neces-
sary information together for the discovery of biomarkers, diagnostics
and therapeutics. Patient centered research programswith open collab-
orations enable people to work together to achieve the goals of preci-
sion medicine.
Faucett: Only 2–5% of sequencing data is currently actionable. Dis-
covering which medicines will make a difference for particular patients
to represent clinical success points, requires identifying which patients
and what a mutation along with a series of other factors. Moving back
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access to both sets of data are critical.
Rathjen: How the web evolves, and how nation's decide to regulate
patient data will signiﬁcantly impact what data is available to whom to
and thus impact what we can know.
Hirsch:We don't yet have a big data problem in precision medicine.
We have a complex data problem. No health care institution has any-
where near the volume of data that companies like Facebook and Goo-
gle have. The data problems that healthcare currently has are
organizational and political. Many are reluctant to adopt new software
solutions, and so the industry's challenge is how to change legacy atti-
tudes and embrace new solutions.
Naik: Life science, IT and biopharmaceutical companies are all very
interested in mining biodata for in silico drug discovery and drug
repurposing purposes. For this reason they are adopting integrated
approaches that pair genotypic and phenotypic data with analytics.
Optra Systems, for example, is partnering with the IBM Watson con-
sortium to develop a novel NGS platform that will integrate data from
different instruments. Inputting data from public and private reposito-
ries into the Watson engine, applying a deep quality assurance and
analytics is generating results displayed in visualization platforms for
evidence-based medicine. The importance of this approach is that it
not only integrates genomics into clinical practice but it gives clinicians
the evidenced based proof that a particular line of therapy or action is
the best.
Wood: One area of datawarehousing people areworking on isﬁgur-
ing out the types of architectures we need to store not just one genome
per person but many "omes" per person. These data sets will need to be
linked to the EHR. In the health careworld there haven't been resources
to attack these types of problems yet but people are starting to plan
what is needed.
Problems in data quality and interpretation
Experts stressed that we need a hierarchy tomeasure data quality to
make sure that the most accurate data is the actual data for the read.
Data quality is a huge problem because there isn't a gold standard
omic technology yet andwe're using different technologies now somul-
tiple data points are now the norm.
Experts agreed that interpretation is based on research data that
is not well phenotyped. They further agreed that no single lab can inter-
pret an exome or genome. The variance between lab results is em-
blematic. They agreed that laboratories need to work together to call
pathogenicity. Partnerships between laboratories and provider organi-
zations enable the pairing of laboratory reports with clinical outcomes
datawhich is needed to improve interpretation. Accurate interpretation
is limited by the inaccessibility of some data sets. Currently ClinGen
(www.clinicalgenome.org) and the Global Alliance for Genomic Health
are trying to change this.
Elliston: As a systems biologist, I have found that variant interpreta-
tion is extremely challenging evenwhen looking at the relatively simple
case of dominant variants with full penetrance.When we ﬁnd the same
mutation in three different people linked to the phenotype then we are
able to call it and this is a relatively low bar. But when you are looking
for the same mutation in non-descended lineages, which is very rare,
you may ﬁnd mutations in the same gene and you may ﬁnd recessive
mutations. The complex system in which genetic variants interact
with each other in the same genome, in the same organ, and in the
same cells makes interpretation very challenging even for a single
genewith a single outcome. For complex diseases, such as neurodegen-
erative diseases, the challenge is far greater. ***You can ﬁnd over 300
genes with dominant or recessive inheritance that cause a particular
neurodegenerative disease phenotype, with thousands of variants
amongst those genes that are incredibly hard to interpret. Even for a
single gene disorder with a functional polymorphism, like Huntington
Disease, we've no treatments today, twenty years after having identiﬁedthe gene. So while correctly annotated variants are useful for managing
clinical outcomes, they may or may not be useful for identifying thera-
peutics, which is why research laboratories and clinics need to work
collaboratively. Moreover, we need to be mindful of the fact that gene
variants are called on the basis of speciﬁc standards, but these standards
change over time further complicating the problem. In the future we
will need to compare, say, the reference genome GRCh35 with version
GRCh37 which will then require a standard for comparison. Further,
we need to think about what we store and why and how it will be
used. We've seen that variants are often called without tracking which
reference genome they are called against. Simply storing variance
alonedoes not enable us to compare one variant against thenext variant
so we need to be careful about the provenance of the data.
Hirsch: Rapid progress is being made on variant interpretation.
Laboratories and provider organizations together can advance variant
interpretation, through the use of aggregated data including clinical
evidence. Healthcare provider systems are uniquely suited to advance
variant interpretation because they can pair laboratory reports with
clinical space history and outcomes data, which connects lab ﬁndings
to variant interpretation. Although independent molecular testing labs
and interpretation companies are also trying to do this, they do not
have access to the clinical evidence needed to conﬁdently interpret
the clinical impact of genomic data. Interpreting based on reading pub-
lished literature is inherently ﬂawed, due to the small sample sizes of
most studies. Population-scale variant interpretation will require popu-
lation-scale clinical studies. We are encourage by the progress that the
Global Alliance for Genomics and Health has made in the past year,
but much more work needs to be done. We at Syapse are helping lead
that charge though our work on population-scale precision medicine
with institutions like Intermountain Healthcare.
Naik: Data curation plays a signiﬁcant role in accurate variant inter-
pretation and its clinical signiﬁcance. From this perspective many tools,
like biological natural language processing, are important to achieving
high quality results. These tools can curate 70–80% of the data semi-
automatically and accurately. Once more such tools are mainstreamed
the authenticity of curation will be improved.
Wood: On the one hand, it's great that new start-ups are selling in-
terpretations. However, caution is needed because these services can't
necessarily be mapped onto a healthcare institutions infrastructure. To
be useful, we need to answer several questions; namelywhat tools phy-
sicians need to interpret and how we do ﬁt that information into daily
clinical workﬂow. In otherwords, we need to look at how interpretation
shouldﬁt into the EHRs.We also need to decidewhether our knowledge
around interpretation is settled science or still evolving. To give you an
example, I'm working on developing an IT infrastructure to house
sequencing information and link it to the EHRs. When we have large
numbers of patients whose sequencing information in the EHRs, we
can then go back and validate where the interpretation came from
and determine whether it's correct or not. This capability will develop
over time. But given the volume of data being generated we need to
solve this problem quickly. We also need to solve the standardization
problem soon to avoid physicians ordering repeat tests because they
don't trust a lab result.
Faucett: All clinical laboratories need their data to be standardized
and need to input phenotypic data to go along with it. The problem
now is that interpretation is often based on research data and research
data isn't phenotyped well. Further, no single lab can develop the inter-
nal database to interpret an exome or a genome. The variance within
and across lab results is telling. Some labs take a lot of time to call a var-
iant and have a low variant-of-uncertain-signiﬁcance rate, while others
don't and still others are unwilling to make a call. ClinVar and ClinGen
are developing a system to capture the evidence behind interpreta-
tion, which will permit you to see if an interpretation was reported
by a single lab, or two labs and if the latter case, whether it was re-
ported consistently. It can also enable you to see whether an inter-
pretation was reported by more than two labs, in which case you
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evidence-based guidelines for interpretation so we can determine
whether this is the variant we're calling pathogenic and what our level
of certainty is that our call is correct. In sum, labs need to work more
closely together.
Rathjen:A separate challenge is the fact that the information changes
so fast and this speed will continue for a long time.
Machine learning, curation and knowledge generation
Experts agreed that big data in precision medicine will become not
only more coordinated but that interpretation and validation require
machine learning. But the ﬁeld is in its infancy.
Elliston:We've learned that trying to reproduce research results re-
quires considerable work, and the results are not always reproducible.
Many believe that these irreproducible results are just bad experiments.
The problem is that rather than cherry picking results, we need to learn
directly from all of the data in a hypothesis free mode. This is why ma-
chine learning will be an invaluable tool for biology. In biology, context
matters, and the conﬂuence of factors in dynamic interplay can be accu-
rately interpreted by intelligent systems that look for the relationships
between variables. The challenge is how to do this in the right ways
with the right data and then to understand what we've learned. This is
a new area of research, and one that is going to be growing very rapidly
in the healthcare space.
Rathjen: I have a vision of self-organizing genomes with real time
consent that enables big data to be coordinated. Much of the literature
is based on small samples, and not replicable. That alone is not motiva-
tion to sort through studies to decide which are good or bad, given that
we can create something so much more robust in the future.
Hirsch: Machine learning may be the future, but machine learning
on what? Presently, health IT is consumed by meeting Meaningful Use
2, and many more requirements are coming. Precision medicine,
complex clinical decision support, population health, machine learning,
and learning health systems are beyond the scope of what EHRs can
handle. In order to implement something as simple as enterprise-wide
pharmacogenomics clinical decision support interfacing with the EMR,
Syapse softwaremust do all of the complex genomics rules calculations
and serve the simpliﬁed decision support into the EHR, because the EHR
is not capable of handling the necessary rules logic. It will be interesting
to see how EHR vendors decide to handle genomic data storage and
integrate the complex logic needed to drive decisions in the clinical
genomic space.
Naik: The machine learning that exists today is a baby step towards
the future and its not just the content produced that is important, it's the
context.
Faucett: I would say we need to continue to work on usingmachine
learning for curation but machine learning has much to learn before it
can effectively be used to combine clinical curation and expert mining
of phenotypic data. We already have examples of people known to
have pathogenic sequences but not disease. If you look at their clinical
history they have problems but have not been diagnosed so they're dis-
ease free and don't ﬁt the classic phenotype. This shows that we need to
go back and forth between clinical and research data if we're going to
correctly annotate variants. I view machine learning as a screening
tool that helps us identify what we need to look at further. It may also
help us identify a clinical signiﬁcance so that we don't need to curate
every variant, at least for the near future.
Wood: I look at machine learning as an intelligent capability built
into the EHRs. To date the only intelligence we've built into the EHR is
decision support that's been mainly risk algorithms around clinical
data. The need to clinically use omic data creates an opportunity to
take this to the next level. At the Institute of Medicine Collaborative
we are working with EHR vendors to determine what they need to
start storing genomic data in the EHR in order to create a standard
which all vendors can use. The HL7 group established standards severalyears ago so the IOM collaborative has established 22 minimum data
elements that need to reside in the HER. We are in the process of map-
ping these requirements onto the HL7 standards.
We can't store genomic data the way we store lab results in the
EHRs. If all we needed was a single gene we could use the same stan-
dard. The structure I envision enables a physician who needs genomic
data in order to make the best decision for a patient, whether it be to
diagnose a disease, identify disease risks or prescribe the right drug. A
physician would be able to link to a repository containing the patient's
omic data, ﬁnd the needed information and link back out to the EHR,
or enter the genomic information in the EHR and enter the decision.
For example, if a physician is assessing a patient's risk for colon cancer
they may want to see if the patient has KRAS mutations, so they link
out to the repository, ﬁnd the answer, and put it into the EHRs. Some
say this is toomuch automated intelligence because it's a mistake to ex-
clude clinical geneticists in this process.
Data access & consent
Elliston: Although the patient consent landscape is changing, these
consents are currently a limitation to realizing the value of patient
data. In personalizedmedicinewehave to trackwhich consents patients
have given and for which analyses in order to know what we can and
cannot do with their data. If you look outside this domain to see how
consent is handled with other types of big data, the situation is entirely
different. In Facebook, your consent was probably tacit; a click-thru
terms of service agreement that you likely did not even read or really
agree to. In this case, sharing your data doesn't beneﬁt you or the
community in the least. It only beneﬁts the vendor and its customers
(advertisers). With healthcare data, you are not presented with a
click-thru consent option and most people don't realize that their data
is being restricted. I think this is all upside down. We should be able
to restrict how our data is used on Facebook and share our healthcare
data so that people can work on treating and curing disease. This is of
true social beneﬁt. I think this consent issue is one of the major socio-
economic barriers to moving genomic medicine to the next level.
Hirsch: When we implement our software to support a precision
medicine program in a healthcare organization, the healthcare organi-
zation typically puts in place a consent infrastructure that allows data
to be used for research and clinical purposes. Though there is tremen-
dous variability across our customer set on this front, and one of the
challenges our industry faces is variability of informed consents and
IRBs. Regarding patient motivations, our customers have found that pa-
tients are willing to share data if it helps advance research into diseases
that impact them or their families.
Faucett: I think most people are willing to consent to broad use of
their data, but they want to know about it. Some aren't and consent
needs to have provisions that permit these people to opt-out. The im-
portant point is that historically consent is implied and the process is
not transparent. Consenting does cost a bit but we need to make it ex-
plicit in our practice. Research supports the notion that most people
will share their data. People want to be sure that the right guardianship
is in place and for this reason it's important that we are transparent be-
cause transparency builds trust and trust promotes data sharing. The
public knows we can't guarantee the privacy of their data but that
we can do our best to protect it and we need to be clear about how
weprotect it. This is particularly true since every day the public is seeing
privacy breaches.
Moving towards patient centric care
Experts agreed that patient centric care requires patients owning
and controlling their data and that health care institutions will be
moving in this direction. Patient centric care also will involve moving
between research and clinical data. Patients, for example, are likely to
ask their physicians for their clinical opinions about sequences
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means that patients will contribute to their data and take an active
role in better understanding their health challenges and improving
their outcomes. In the future peoplewill manage their care on theirmo-
bile devices so the data needs to be accessible and linked to disparate
entities. As patients contribute to their data, we will begin to focus on
families and not just individuals.
In sum, the panel agreed that some important shifts have already
occurred. Data storage is transitioning from warehouses to the cloud as
organizations are increasingly convinced of cloud security. Organizationshave moved from being opposed to open source solutions to embracing
them and collaborative platforms. Data integration is increasing because
we are adopting integrated approaches. Precision medicine will adapt
the big data volume solutions being pioneered by the companies, like
Google, Amazon, Microsoft or Rackspace, that are wrestling with how to
design software on cloud. The data complexity problem, however, will
be Precision Medicine's challenge to solve. In the future we will always
use mined data and we can move forward to create a learning health
care system if we all work together.
